Trial Profile
Randomized, Placebo-Controlled Study of Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Danicamtiv (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions; First in man
- Sponsors MyoKardia
- 30 Oct 2018 Results presented in a MyoKardia media release.
- 08 Mar 2018 Status changed from recruiting to completed according to a MyoKardia media release.
- 14 Feb 2018 According to a MyoKardia media release, detail results (n=64) from this study will be present at a future medical meeting.